# Stereotactic Ablation Radiotherapy Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer

> **NCT04840758** · PHASE1,PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 39 (estimated)

## Conditions studied

- Multiple Primary Lung Cancer

## Interventions

- **RADIATION:** Stereotactic Ablation Radiotherapy
- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT04840758
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06
- **Primary completion:** 2022-12
- **Final completion:** 2023-04
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2021-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04840758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04840758, "Stereotactic Ablation Radiotherapy Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04840758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*